Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Molecular Pharmacology
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Molecular Pharmacology

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Visit molpharm on Facebook
  • Follow molpharm on Twitter
  • Follow molpharm on LinkedIn

Table of Contents

November 01, 1984; Volume 26,Issue 3
  • You have access
    Muscarinic cholinergic receptors of two cell lines that regulate cyclic AMP metabolism by different molecular mechanisms.
    T Evans, M M Smith, L I Tanner and T K Harden
    Molecular Pharmacology November 1984, 26 (3) 395-404;
  • You have access
    The relationship between phosphatidylinositol metabolism and mobilization of intracellular calcium elicited by alpha1-adrenergic receptor stimulation in BC3H-1 muscle cells.
    S K Ambler, R D Brown and P Taylor
    Molecular Pharmacology November 1984, 26 (3) 405-413;
  • You have access
    Purification and characterization of (-)[125I]hydroxyphenylisopropyladenosine, an adenosine R-site agonist radioligand and theoretical analysis of mixed stereoisomer radioligand binding.
    J Linden
    Molecular Pharmacology November 1984, 26 (3) 414-423;
  • You have access
    Use of a density shift method to assess beta-adrenergic receptor synthesis during recovery from catecholamine-induced down-regulation in human astrocytoma cells.
    G L Waldo, R C Doss, J P Perkins and T K Harden
    Molecular Pharmacology November 1984, 26 (3) 424-429;
  • You have access
    [3H]Ro 22-1319 (piquindone) binds to the D2 dopaminergic receptor subtype in a sodium-dependent manner.
    T Nakajima and K Iwata
    Molecular Pharmacology November 1984, 26 (3) 430-438;
  • You have access
    Distinctions between ligand-binding sites for [3H]dopamine and D2 dopaminergic receptors characterized with [3H]spiroperidol.
    A A Hancock and C L Marsh
    Molecular Pharmacology November 1984, 26 (3) 439-451;
  • You have access
    Further characterization of structural requirements for agonists at the striatal dopamine D2 receptor and a comparison with those at the striatal dopamine D1 receptor. Studies with a series of monohydroxyaminotetralins on acetylcholine release from rat striatum.
    M P Seiler and R Markstein
    Molecular Pharmacology November 1984, 26 (3) 452-457;
  • You have access
    Anxiolytic cyclopyrrolones zopiclone and suriclone bind to a novel site linked allosterically to benzodiazepine receptors.
    R R Trifiletti and S H Snyder
    Molecular Pharmacology November 1984, 26 (3) 458-469;
  • You have access
    Anxiolytic cyclopyrrolone drugs allosterically modulate the binding of [35S]t-butylbicyclophosphorothionate to the benzodiazepine/gamma-aminobutyric acid-A receptor/chloride anionophore complex.
    R R Trifiletti, A M Snowman and S H Snyder
    Molecular Pharmacology November 1984, 26 (3) 470-476;
  • You have access
    Binding of [3H]naloxonazine to rat brain membranes.
    N Johnson and G W Pasternak
    Molecular Pharmacology November 1984, 26 (3) 477-483;
  • You have access
    Benzomorphan sites are ligand recognition sites of putative epsilon-receptors.
    K J Chang, S G Blanchard and P Cuatrecasas
    Molecular Pharmacology November 1984, 26 (3) 484-488;
  • You have access
    Opiate-receptor interactions on single locus coeruleus neurones.
    J T Williams and R A North
    Molecular Pharmacology November 1984, 26 (3) 489-497;
  • You have access
    Evidence for agonist-induced interaction of angiotensin receptor with a guanine nucleotide-binding protein in bovine adrenal zona glomerulosa.
    A De Léan, H Ong, J Gutkowska, P W Schiller and N McNicoll
    Molecular Pharmacology November 1984, 26 (3) 498-508;
  • You have access
    Cellular pathways of galactose-terminal ligand movement in a cloned human hepatoma cell line.
    C F Simmons and A L Schwartz
    Molecular Pharmacology November 1984, 26 (3) 509-519;
  • You have access
    Molecular structures of metabolites and analogues of diethylstilbestrol and their relationship to receptor binding and biological activity.
    W L Duax, D C Swenson, P D Strong, K S Korach, J McLachlan and M Metzler
    Molecular Pharmacology November 1984, 26 (3) 520-525;
  • You have access
    Progesterone inhibition of Xenopus oocyte adenylate cyclase is not mediated via the Bordetella pertussis toxin substrate.
    S E Sadler, J L Maller and D M Cooper
    Molecular Pharmacology November 1984, 26 (3) 526-531;
  • You have access
    Cannabinoid inhibition of adenylate cyclase. Pharmacology of the response in neuroblastoma cell membranes.
    A C Howlett and R M Fleming
    Molecular Pharmacology November 1984, 26 (3) 532-538;
  • You have access
    Comparison of the sodium dependency of uptake of meta-lodobenzylguanidine and norepinephrine into cultured bovine adrenomedullary cells.
    S Jaques, M C Tobes, J C Sisson, J A Baker and D M Wieland
    Molecular Pharmacology November 1984, 26 (3) 539-546;
  • You have access
    Genetic influences on the central nervous system depressant and membrane-disordering actions of ethanol and sodium valproate.
    B J Perlman and D B Goldstein
    Molecular Pharmacology November 1984, 26 (3) 547-552;
  • You have access
    The effect of aliphatic adenine analogues on S-adenosylhomocysteine and S-adenosylhomocysteine hydrolase in intact rat hepatocytes.
    J S Schanche, T Schanche, P M Ueland, A Holý and I Votruba
    Molecular Pharmacology November 1984, 26 (3) 553-558;
  • You have access
    Inhibition of erythrocyte sickling by thiol reagents.
    M C Garel, C Domenget, F Galacteros, J Martin-Caburi and Y Beuzard
    Molecular Pharmacology November 1984, 26 (3) 559-565;
  • You have access
    Effect of cytosolic components on the metabolism of the hydrazide iproniazid.
    M E Spearman, S J Moloney and R A Prough
    Molecular Pharmacology November 1984, 26 (3) 566-573;
  • You have access
    Reducing equivalents for mixed function oxidation in periportal and pericentral regions of the liver lobule in perfused livers from normal and phenobarbital-treated rats.
    S A Belinsky, F C Kauffman and R G Thurman
    Molecular Pharmacology November 1984, 26 (3) 574-581;
  • You have access
    Free radicals in quinone-containing antitumor agents. Electrochemical reduction of diaziquone (2,5-diaziridine-3,6-bis(carboethoxyamino)-1,4 -benzoquinone) and two analogues.
    P L Gutierrez, B M Fox, M M Mossoba and N R Bachur
    Molecular Pharmacology November 1984, 26 (3) 582-586;
  • You have access
    Metabolic competition studies of 2'-fluoro-5-iodo-1-beta-d-arabinofuranosylcytosine in vero cells and herpes simplex type 1-infected vero cells.
    T C Chou, C Lopez, J M Colacino, A Feinberg, K A Watanabe, J J Fox and F S Philips
    Molecular Pharmacology November 1984, 26 (3) 587-593;
  • You have access
    Long term instability and molecular mechanism of 5-azacytidine-induced DNA hypomethylation in normal and neoplastic tissues in vivo.
    L J Lu and K Randerath
    Molecular Pharmacology November 1984, 26 (3) 594-603;
Back to top
PreviousNext

In this issue

Molecular Pharmacology
Vol. 26, Issue 3
1 Nov 1984
  • Table of Contents
  • Table of Contents (PDF)
  • Index by author
  • Back Matter (PDF)
  • Editorial Board (PDF)
  • Front Matter (PDF)
Sign up for alerts
  • Most Cited
  • Most Read
Loading
  • SB-431542 Is a Potent and Specific Inhibitor of Transforming Growth Factor-β Superfamily Type I Activin Receptor-Like Kinase (ALK) Receptors ALK4, ALK5, and ALK7
  • The G-Protein-Coupled Receptors in the Human Genome Form Five Main Families. Phylogenetic Analysis, Paralogon Groups, and Fingerprints
  • Pharmacological Properties of Y-27632, a Specific Inhibitor of Rho-Associated Kinases
  • Pharmacological characterization of five cloned voltage-gated K+ channels, types Kv1.1, 1.2, 1.3, 1.5, and 3.1, stably expressed in mammalian cell lines.
  • The Orphan Human Pregnane X Receptor Mediates the Transcriptional Activation of CYP3A4 by Rifampicin through a Distal Enhancer Module
More...
Advertisement
  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About Molecular Pharmacology
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Drug Metabolism and Disposition
  • Journal of Pharmacology and Experimental Therapeutics
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-0111 (Online)

Copyright © 2023 by the American Society for Pharmacology and Experimental Therapeutics